Stockscreener 앱 받기
15.83
0.51%
0.08
전일 마감가:
$15.75
열려 있는:
$15.51
하루 거래량:
144.25K
Relative Volume:
0.75
시가총액:
$1.02B
수익:
-
순이익/손실:
-
주가수익비율:
-15.73
EPS:
-1.0062
순현금흐름:
-
1주 성능:
+3.60%
1개월 성능:
+11.79%
6개월 성능:
+126.47%
1년 성능:
+831.18%
1일 변동 폭
$14.70
$16.05
1주일 범위
$14.70
$16.95
52주 변동 폭
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
15.83 | 1.02B | 0 | 0 | 0 | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Leerink Partners | Outperform |
| 2026-02-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | 개시 | H.C. Wainwright | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr 주식(ANL)의 최신 뉴스
Adlai Nortye at Morgan Stanley global healthcare conference: RAS push By Investing.com - Investing.com South Africa
Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale - Stock Titan
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Australia
Adlai Nortye (NASDAQ: ANL) Initiates Global Phase I Trial for AN4035 with Phase Ia Data Expected in Late 2027 - Kalkine Media
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - investing.com
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial - Investing.com
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com - Investing.com Nigeria
Adlai Nortye expands scientific advisory board with two oncologists - Investing.com
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0 - TradingView
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL) - TradingView
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
ANL Stock Price, Quote & Chart | ADLAI NORTYE LTD-ADR (NASDAQ:ANL) - ChartMill
Adlai Nortye initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Adlai Nortye stock coverage with Outperform By Investing.com - Investing.com Nigeria
Adlai Nortye Ltd Adr (ANL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):